Lin BioScience, Inc.(TW:6696)
NT$166.50+3.50 (+2.15%)
TW:6696
Lin BioScience, Inc. financials statements
NT$166.50
At close:+3.50 (+2.15%)
Lin BioScience, Inc. (6696) Ratios
Lin BioScience, Inc. Ratios
TW:6696's free cash flow for Q2 2026 was NT$-1.26B. For the 2026 fiscal year, TW:6696's free cash flow was decreased by NT$-20.46M and operating cash flow was NT$-1.24B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 58.18 | 34.45 | 24.69 | 20.94 | 1.74 |
| Quick Ratio | 58.18 | 34.45 | 24.69 | 20.94 | 1.74 |
| Cash Ratio | 42.10 | 9.58 | 23.51 | 20.60 | 1.72 |
| Solvency Ratio | -4.60 | -4.18 | -3.99 | -2.61 | -0.92 |
| Operating Cash Flow Ratio | -5.10 | -6.56 | -7.30 | -4.52 | -0.62 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -0.69 |
| Net Current Asset Value | NT$ 16.16B | NT$ 5.18B | NT$ 3.26B | NT$ 1.56B | NT$ 349.29M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.02 | 0.04 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.02 | 0.04 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.37 | 1.94 | 1.68 | 1.50 | 1.70 |
| Debt Service Coverage Ratio | -2516.49 | -1505.56 | -859.47 | -511.32 | -1.14 |
| Interest Coverage Ratio | -2812.04 | -1456.22 | -904.97 | -508.72 | -4764.46 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 |
| Interest Debt Per Share | 0.29 | 0.45 | 0.59 | 0.66 | 0.03 |
| Net Debt to EBITDA | 4.55 | 1.01 | 3.00 | 3.43 | 1.66 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 51.68% | 56.03% | 63.01% | 65.61% | 88.64% |
| EBT Per EBIT | 92.29% | 91.13% | 99.43% | 107.36% | 144.97% |
| Return on Assets (ROA) | -5.36% | -13.47% | -19.11% | -16.93% | -47.08% |
| Return on Equity (ROE) | -12.70% | -26.07% | -32.15% | -25.40% | -80.27% |
| Return on Capital Employed (ROCE) | -11.36% | -27.14% | -31.72% | -25.12% | -74.68% |
| Return on Invested Capital (ROIC) | -11.12% | -27.05% | -30.73% | -24.01% | -38.02% |
| Return on Tangible Assets | -5.38% | -13.76% | -19.70% | -17.99% | -52.62% |
| Earnings Yield | -42.14% | -68.86% | -79.88% | -25.56% | -34.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -17.69 | -12.97 | -13.60 | -5.03 | -4.15 |
| Free Cash Flow Per Share | -17.79 | -13.06 | -13.62 | -5.34 | -4.18 |
| Dividend Paid and CapEx Coverage Ratio | -176.32 | -138.76 | -515.43 | -16.13 | -136.65 |
| Capital Expenditure Coverage Ratio | -176.32 | -138.76 | -515.43 | -16.13 | -136.65 |
| Operating Cash Flow Coverage Ratio | -63.19 | -29.99 | -23.62 | -7.76 | -129.33 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -44.82% | -94.99% | -117.96% | -31.26% | -22.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.37 | -1.45 | -1.25 | -3.91 | -2.93 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.30 | 0.38 | 0.40 | 0.99 | 2.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.23 | -1.05 | -0.85 | -3.20 | -4.36 |
| Price-to-Operating Cash Flow Ratio | -2.24 | -1.06 | -0.85 | -3.40 | -4.39 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | -0.56 | -0.01 | 0.13 | -0.02 |
| Enterprise Value Multiple | 3.31 | 0.26 | 2.20 | 0.80 | -0.96 |
| Enterprise Value | -8.65B | -373.38M | -2.36B | -372.06M | 468.47M |
| EV to EBITDA | 3.31 | 0.26 | 2.20 | 0.80 | -0.96 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 5.97 | 0.36 | 2.32 | 0.97 | -1.60 |
| EV to Operating Cash Flow | 6.00 | 0.37 | 2.33 | 1.03 | -1.62 |
| Tangible Book Value Per Share | 307.12 | 66.61 | 44.57 | 22.68 | 5.10 |
| Shareholders’ Equity Per Share | 131.74 | 36.32 | 28.70 | 17.20 | 7.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | -0.05 | 0.03 | 0.04 | 0.02 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -16.73 | -9.47 | -9.23 | -4.37 | -6.23 |
| Tax Burden | 0.52 | 0.56 | 0.63 | 0.66 | 0.89 |
| Interest Burden | 1.00 | 0.91 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.55 | 0.77 | 0.93 | 0.76 | 0.67 |
Currency in TWD
